Tobacco Documents Online

WSAHNBIFO 2001 PLAN P. Leader P.Number ProjectName Ob/ective Deliverable Guidance Area Status per RPS / Comments WSA/INBIFO 2001 PROPOSED PROJECTS - HARM REDUCTION • TIER 2 McKinney, W NOi 134 Induced sputum biomarkers Identify and validate induced sputum biomarkers using memorandum/report 10-Understanding Smoking and Health -General Start scientific literature. Harm Reduction (Tier 2) Schlage, W N01150 Cytokeratin (CK) Expression in the Respiratory poster, publication 10-Understanding Smoking and Health - General Start Tract of Rats Exposed to RASS or DEE he~rsed-toenhaneeourunde[sianding-of the-eiFects- Harm Reduction (TIer2) evNepment-af tirr disesae}Geneml: Establish intermediate biomarker methods indica6ve ior the potential in vivo carcinog Schramke, H N01199 Mouse Lymphoma TKAssay-Cytotoxicity Understand TK cytotoxicity: lnvestigate the lnfluence of memo 10-Understanding Smoking and Health - General Start cytotoxicity on the mutagenicity results Harm Reduction (7ier2) Weisensee, D N01197 Establishment and Validation of the Ex Vivo hpd Method Development, Cell Biology: Establishment of an Poster/publication 10-Understanding Smoking and Health - Start Assay exvivo hprt mulatlon assay In rattype II cells as a General Harm Reduction (Tier2) genotoxic marker indicative for the potential carcinogenic activity of cigarette smoke in order to complement our acceptance testing battery. Woehrmann, T N07177 Cell Proliferation Study of increasing sensitivity in the rat model by choice of internal memo; subreport 10-Understanding Smoking and Health • Start histopathotogical methods for the Vung: method General Harm Reduction (Tier 2) development, histopathology (to measure induced cell proliferation In specific rodent target organs by immunohistoehemical methods in order to sup Muerrens, K N01170 Transgenic Models and Cigarette Smoke Promotion Index, in vivo: Evaluation of transgenic animal memo 10-Understanding Smoking and Health • Start models (ILSI list), responsiveness of iransgenics to smoke General Harm Reduction (Tier 2) constituents (literature study)-identification of transgenic models of interest PROJECTS PROPOSED AFTER 12-11 PROJECT REVIEW Roemer, E Lactic acid Risk assessment on chemicals which are specific targets DataCompilation,Memo, Needs to be determined Start In harm reduced products; Reproduce and investigate the Poster mechanism of reduced biological activity of mainstream smoke due to the addition of lactic acid to the filler of cigarettes Schlage, W. Biochemical chamcterization of new rat lung Method development, Cell Biology; To characterize cell method development, Cell Needs to be determined Start epithelial cell lines and routinely used lines derived from the target organ (rat lung) with defined Biology nonepithelialcelllines metabolic abilities for the improvement and complementation of standard In vitro assays (e.g., cyletoxicity, gap junctional Intercellular communication), and to characterize the nonepithelial cell lines currently used in such assays (e.g., 3T3 fibroblasts) £9Z405680Z DRAFT FOR REVIEW PURPOSES - V1 9101 Paqe 7

WSMNBIF02001 PLAN P,Leader P. Number ProjectName Objective Deliverable Guidance Area StatusperRPSlComments Kinser, R N01143 Characterization of ETS Exposure in the US To acquire guidance for harm reduction guidance by report; presentation; 08-Understanding Smoking and Health- Start Workplace developing the most scientifically robust method to publication Exposure (Tier 2) characterize exposure to ETS in the workplace based on a comprehensive review of existing data and assessment methodologies by March 2002. Koller, D N01102 GenomicslProteomics To determine if genomics/proteomics technologies can be recommendation 08-Understanding Smoking and Health - Start used to enhance our understanding of the effects of Exposure (Tier 2) smoke constituents on the development of disease Gerstenberg, B N01198 Measures for ETS/SS What would be constituentappropdate measures for Memo 09-Understanding Smoking and Health -Test Start ETS/SS? Systems/Expedmental Models (Tier 2) Stabbert, R N01205 Styrene DNA Adducts Method Development, Analytical Chemistry: In rat lung Memo 09-Understanding Smoking and Health-Test Start homogenates from the RASS/DEE study, styrene DNA Systems/Experimental Models (Tier 2) adducts will be quantified eitherby ESI/MS orby ICP/MS. WSAIINBIFO 2001 PROPOSED PROJECTS - OTHER Elves, R N01135 Free Radicals Scavenging for Smoke Screening studies to determine the relationship and possible SCoR needs to be determined George-Is this a go? effectiveness of free radical scavengers (i.e. phenyl-Ndert- recommendation for butylnitrone,PBN administration prior, during and after selective filtration and smoking exposures in vitro (particulate and gas vapor publication phase) and in vivo (21 day inhalation exposures) to reduce injury. Successful outcome may be applied for use as a selective filter agent for harm reduction or for use in chemoprevenllon. I WSA/MBIF02001 PROPOSED PROJECTS - HARM REDUCTION - TIER 1 I Tricker, A N01299 Molecular Epidemiology Studyfor Oasis in Japan To-desigrt a molecular epidemiology study that might study on biomarkers of 05-Understanding Smoking and Health-General Stad confirm harm reduction for Oasis smokers in Japan and effect in Oasis smokers Harm Reduction (Tier 1) submission of study design plan to the SRRC by December 1, 2001. The deliverable should not just be a study plan, but a study. First milestone may be a plan in 2001. Tewes, F(Roemer, N01124 Parameter 3: Blends Parameter Studies: Publish the influence of single bland repeds; pWlication 05-Understanding Smoking and Health - General Stad components on the chemical composition and in vitro Harm Reduction (Tier 1) toxicity of cigarette mainstream smoke Roemer, E N01125 Parameter 2: Brands Parameter Studies: Determine the chemical composition reports; publication 05-Understanding Smoking and Health - General Start and biological activity of mainstream smoke of brand Harm Reduction (Tier 1) cigarettes Roamer, E N01123 Parameter 4: Filter Parameter Studies: Investigate the Influence of different poster 05-Understanding Smoking and Health - General Start filter types, e.g., carbon or silica, on the biological activity Harm Reduction (Tier 1) of cigarette smoke. Takada, K N01138 Plan Oasis Exposure Study DGter,T,n,~thefeesibiNtyef conducting said study in Oasis study plan 05-Understanding Smoking and Health - General Start smokers inJapan. Harm Reduction (Tier 1) The deliverable should not just be a study plan, but a study. First milestone may be a plan in 2001. -- I ORAFrFORREVIEWPURPOSEa-V7e/07 ' 4~•Z~,O9J~,gOZ I Page5 7

WSAIINBIF02001 PLAN P. Leader P. Number Project Name Objective Deliverable Guidance Area Status per RPS I Comments Mueller, T N01190 Oxidative Stress Induced by Cigarette Smoke Understanding apoprosis/necrosis: To understand publication 04-Understanding Smoking and Health - Test Start initiation ot and signal-transductlon in smoke-bubbled PBS SystemsfExperimental Models (Tier 1) exposed cells in terms of cellular fate, i.e., apoptosis/necrosis; special emphasis will be placed on the role of heme oxygenase (HO-1) expression Klndt, R. N01187 Induction of Apoptosis, Necrosis, and Cell Cycle Understanding apoptosislnecrosis, single components: To Documentation 04-Understanding Smoking and Health -Test Start Arrest by Selected Cigarette Smoke Components investigate the potency of selected cigarette smoke Systems/Experimental Models (Tier 1) in Vitro components to induce apoptosis, necrosis, and cell cycle arrest in vitro; compare the mode of cytotoxic action with that of cigarette smoke (-preparations Mueller, T N011S6 Oxidative Stress Induced by Cigarette Smoke To understand the initiation of and signal transduction in Publication 04-Understanding Smoking and Health - Test Start , smoke-bubbled PBS-exposed cells in temts of cellular Systems/Experimental Models (Tier 1) fate, i-e., apcptosis or necrosis: Role of glutathlone (GSH)/GSH reduotase and thioredoxin (Trx)/Trx reduotase (TrxR) system, respectively Reininghaus, W N01171 New Models and Markers for Tumor Promotion in Promotion index, in vivo: To improve our understanding of literature review (internal); 05-Understanding Smoking and Health- General Start the Lung the potential mechanisms leading to lung cancer (initiation, publication (if appropriate) Harm Reduction (Tier 1) promotion) and to identify possible new endpoints for in vivo and in vitro testing, e.g., markers of altered intercellular communication Vanscheeuwijck, P N01172 Identification of Smoke Constituents Playing a CVD index, in vivo: Identification of smoke constituents memo g5-Understanding Smoking and Health - General Start (project leaders resolved Role in CVD playing a role in CVD-literatum study Harm Reduction (Tier 1) overlap) WSNINBIFO 2001 PROPOSED PROJECTS - UNDERSTANDING S&H -TIER 2 Dempsey, R N01090 Case control study of ETS and lung cancer To design a case-control study examining the association study designlprotecel 06-Understanding Smoking and Health - Start of ETS and lung cancer that will address, to the extent Epidemiology (Tier 2) t-ETSand- possible, all systematic biases, by January 2003 and have The deliverable should not Lttag6eneer study initiated just be a study plan, but a study. First milestone may be a plan in 2001. Dempsey, R N01099 ETS Exposure and Infections in Childhood T research fnte- literature database; review 06-Understanding Smoking and Health - Start . factorsaffectingseverity,frequencyandsequelaeof otthelHemturewithgap Epidemiology (Tier 2) childhood respiratory infections and the potential role analysis;iesearefh played by ETS by the third quarter of 2001. prepesals Dempsey, R N01100 Scientific Consensus-Maternal Smoking During Summarize-whe~ the potential health scientific consensus 06-Understanding Smoking and Health - Start Pregnancy effects to the child ot maternal smoking during pregnancy. document Epidemiology (Tier 2) Dempsey, R N01097 Review of Longitudinal Studles on ETS Exposure To provide a complete summary and analysis of the major literature review and 06-Understanding Smoking and Health - Start and Respiratory Health of Children longitudinal studies with data on ETS exposure during analysis; future research Epidemiology (Tier 2) childhood, identifying trends in time, exposure sources proposals and respiratory endpoints and indicating potential models as the basis for future research by end of 3rd quarter 2002. Sanders, E N01101 Comparative analysis of CPS-I and CPS-II studies To perform a thorough analysis of the two CPS studies in report 06-Understanding Smoking and Health - Start order to attempt to explain, as best as possible, the Epidemiology (Tier 2) differences in results between the two studies in order to obtain mechanistic insight on active smoking and lung cancer by end of 2001. eRAFfFORREVIEWPURPpSES-1/191e1 I 6YZY05YOQZ I Page3

WSAlINBIF02001 PLAN P. Leader P. Number Project Name Objective Deliverable Guidance Area Status per RPS/ Comments Elves, R N01144 Transdermal Patch Biomonitoring Evaluate the use of commercially available transdermal publication; possible 05-Understanding Smoking and Health - General Start patch technologies (i.e., PharmChek, Band Aid, gcp/glp assay Harm Reduction (Tier 1) Sudormed) for use as a non-invasive method of human blomonitoring of exposure to smoke constituents. Walk, R N01148 Total Exposure Study in U.S. Measure the uptake of selected vapor phase and report; publication 05-Understanding Smoking and Health- General Start particulate smoke components toran appropriate U.S. Harm Reduction (Tier 1) population based on suitable biomarker(s). Haussmann, H N01175 Validation of AJJ Model Definitive evaluation of the NJ Mouse model: Develop a concept; application 05-Understanding Smoking and Health- General Start concepttodefinifinelyvalidateorinvalldatetheNJmouse HarmReduction(Tieri) model for cigarette smoke inhalation beyond the pair- feeding study Haussmann, H N91178 Potential Improvement of Sensitivity in Rodent Study of increasing sensitivity in the rat model by choice of recommendation; 05-Understanding Smoking and Health - General Start Cigarette Smoke Tumorigenicity Studies by Step- histopathological methods for the lung publication Harm Reduction (Tier 1) Serial Sectioning of the Lung Kuhl, P N0t193 Method Development, Paraoxanase Method Development, Biochemistry: For CVD biomarker SOP 05-Understanding Smoking and Health - General Start determination a biochemical method for oxidative damage, Harm Reduction (Tier 1) i.e., paraoxanase activity in blood plasma will be developed Kuhl, P N01192 Method Development, Antioxidant Activity Method development, biochemistry: For CVD biomarker SOP 05-Understanding Smoking and Health - General Start . determination a biochemical method for oxidative damage, Harm Reduction (Tier 1) i.e., the total antioxidant activity In blood plasma will be developed. Reininghaus, W N01179 Development of In Vivo Model(s) for To identify and develop suitable in vivo model(s) for collaboration with 05-Understanding Smoking and Health- General Start Cardiovascular Disease cardiovascular disease symptom(s) and blomarkers of consultants and external Harm Reduction (Tier 1) effect in cigarette smoke-exposed rodents laboratories; study plans Stinn, W N01176 NJ Mouse Definifive evaluatlon of NJ Mouse: Investigate the report/publication 05-Understanding Smoking and Health- General Start spontaneous and urethane-induced lung tumorigenicity, as Harm Reduction (Tier 1) well as ras mutation pattern in NJ mice after chronic ETS exposure or food restricGon Vanscheeuwijck, P N01180 Follow-up Atherosclerosis in ApoE Null Mice Development of CVD in vivo models: Follow-up and memo; presentation 05-Understanding Smoking and Health - General Start support of external project (K.U. Leuven) with ApoE null Harm Reduction (Tier 1) mice with regard to atherosclerosis Veltel, D N01191 Cytotoxicity Index from Single Smoke Understanding cytotoxicity, smoke constituents documentation 05-Understanding Smoking and Health - General Start Constituents In Vitro Harm Reduction (Tier 1) Weber, S Ng1196 Single Cell Gel Electrophoresis (Comet) Assay Method Development, Cell Biology: Establishing of the SOP 05-Understanding Smoking and Health- General Start Comet-Assay as an in vitro genotoxicity, assay for Harm Reduction (Tier 1) detection of DNA-damage in single cells. Haussmann, H Ng1173 Concept for the Toxicological Weighting of Complete, refine, and publish the concept for the publication 05-Understanding Smoking and Health- General Start Cigarette Smoke Constituents weighting approach for cigarette smoke constituents on Harm Reduction (Tier 1) the current smoke chemistry list, with special emphasis on carcinogenicity Kinser, R N01164 RepeatabilityandReproducibilltyAssessmentfor DevelopageneralapproachfordemonstraBng repeata bilitylreproducibility 05-Understanding Smoking and Health - General Start Analytical Methods for Human Studies repeatabllity and reproducibility of analytical methods to be assessment plan; input to Harm Reduction (Tier 1) utilized in Human Studies projects by March 31, 2001. study design' presentationslpublications Oay, J N01169 Biomarkers of Exposure forAccrortl in US Exploratory study of changes in biomarkers of exposure in report and publication: 05-Understanding Smoking and Health - General Start smokerswhoswitchfromsmokingconvenGonalcigarettes resultsofcontrolled HarmReduction(Tier1) , io Accord in US: Phase 1) Controlled switch (controlled in switchers by2002 ' terms of the number of cigarettes smoked per day); Phase ZMQMIDZ ~ 2)Follow-upoftheswitc DRAFr FOR REVIEW PURPOSES - ina/ol Page 6

WSA/INBIF02001 PLAN I WSMNBIFO 2001 PROPOSED PROJECTS - UNDERSTANDING S&H - TIER 1 1 P. Leader P. Number Project Name Objective Deliverable Guidance Area Status per RPS/ Comments Dempsey, R N01106 Epidemiology of lung cancer in smokers of ultra- 9esigrt an epidemiological study on the association of study design/protocof 01-Understanding Smoking and Health - Project leaders should reso{ve low tar cigarettes (1-5 mg) lung cancer in smokers of ultra low tarcigarettes (1-5 mg) Epidemiology (Tier 1) overlap between projects 1106, compared to smokers of higher tar cigarettes by October 1107, 1109, 1116, 1117 2001. The deliverable should not just be a study plan, but a study. First milestone may be a plan in 2001 Sanders, E N01109 Analysis lung cancer relative risk associated with To identify possible factors that would appear to either report; publications 01-Understanding Smoking and Health - Project leaders should resolve active smoking and incidence among different increase or decrease the smoking associated risk for lung Epidemiology (Tler 1) overlap between projects 1106, regional and ethnic groups cancer to obtain key mechanistic insights. The inhial work 1107, 1109, 1116, 1117 will concentrate on Japanese smokers with a planned completion date of end of 2001 Sanders, E N01107 Association of adenecareinoma with active To analyze epidemiological data on the association of flnal report; possible harm 01-Understanding Smoking and Health - Project leaders should resolve smoking adenocarcinoma with active smoking with particular reduction guidance Epidemiology (Tier 1) overlap between projects 1106, emphasis on low tar cigarettes to possibly be able to guide 1107,1109,1116,1117 Product Development with respect to the development of novel filters by the fourth quarter of 2001 Sanders, E N01100 Epidemiology of Active Smoking and CVD To fully analyze the epidemiological literature regarding report 01-Understanding Smoking and Health - Start (project leaders resolved aclive smoking and various CVD endpoints by the 4th Epidemlology (Tler 1) overlap) quarter 2001. Schorp, M N01110 Active smoking and COPD Carry out detailed analysis of CCPD epidemiological review document; 01-Understanding Smoking and Health - Project leaders should resolve studies in order for us to obtain a meaningful recommendations for future Epidemiology (Tier 1) overlap between projects 1110, understanding of the relationship of active smoking with research 1121,1122 COPD, Such information could possibly provide guidance in assay and reduced harm product development Tricker, A N01112 Molecular epidemiology study for smoking To design a moleoular epidemiology study to investigate summery review of smoking 01-Understanding Smoking and Health - Stad cessation changes in biomarkers of exposure and blomarkers of cessation studies; study on Epidemiology (Tier 1) . effect on smoking cessation and submission of study effect of cessation design to the SRRC by March 1, 2002. biomarkers of effeat Kinser, R N01115 Scienfific Consensus - Understanding of Smoke Summarize scientlflcconsensus on the understanding of report; presentations; 02-Understanding Smoking and Health - Hazard Start Nitrosamine Sources smoke nitrosamine sources by September 30, 2001 publication (Tier 1) Lau, R N01127 Assessment of the role of irritation to establlsh To identify by July 2001 the dose-response presentation to WSA 02-Understanding Smoking and Health-Hazard. Start ETS exposure management level relationship between irritation and ETS exposure in management (Tier 1) humans b . ,.........._- y __.,_...._.. ___. ....,.__..,_ ._. _._ _. _ . _ eunryueneats in -akfier->pe-ind eNerref-humarrkrNetiens- respanses~~e~ McKinney, W N01121 Cigarette Smoke-Induced Chronic Obstructive To understand mechanisms of COPD. To identify target recommendation to HS 02-Understanding Smoking and Health - Hazard Project leaders should resolve Pulmonary Disease (COPD) Target Constituent constituents In smoke which may contribute to COPD. group; review article (Tier 1) overlap between projects 1110, Identlrication 1121, 1122 McKinney, W N01122 Cigarelte Smoke-induced Chronic Obstructive To understand mechanisms of COPD. To identify smoke- recommendation to HS 02-Understanding Smoking and Health - Hazard Project leaders should resolve Pulmonary Disease (COPD) 6iomarker induced COPD biomarkers of effect and host factors of group; review article (Tier 1) overlap between projects 1110, Identification susceptibility to smoke-induced COPD. 1121,1122 DRAFTFORREVIEWPURPOSES-1119/01 ' I - _ LtZ6U9tgOZ If Paga1

WSA/INBIF020B1 PLAN P,Leader P. Number Project Name Objective Deliverable Guidance Area Status per RPS / Comments Tricker, A N01116 Identification of biomarkers (effect, susceptibillty, To recommend biomarkers of effect, susceptibility, risk, recommendation 02-Understanding Smoking and Health - Hazard Project leaders should resolve risk, and disease) related to lung cancer and/or disease related to lung cancer for use In human (Tier 1) overlap between projects 1106, studies on harm reduced cigarette products by August 1197,1109,1116,1 f 17 2001 Von Holt, K N01114 State of science, including review of the literature To compile a presentation with a reference documentation presentation, reference 02-Understanding Smoking and Health - Hazard Start (project leaders resolved onmolecularepidemiobgystudies,ofthe that summarizes current key hypotheses for the documentation, (Tier 1) overlap) potential mode/mechanisms(s) including disease mechanism and host factors for ischemic heart disease by recommendation to endpolntsandhostfactorsforiscAemicheart October2001 External Research Program disease Von Holt, K N01120 CVD Biomarker identification CVD Biomarker ldentification Group: Review and evaluate consmstts document 02-Understanding Smoking and Health - Hazard Start (project leaders resolved literature on OVD and compile information from experts in (Tier 1) overlap) the field in order to consolidate the existing Iistof CVD biomarkers and identify suitable additional candidates Walk, R N01117 State of science including review of the literature To compile a presentation with a reference documentation presentation, reference 02-Understanding Smoking and Health - Hazard Project leaders should resolve on molecular epidemiological studies, of the thatsummarizes current key hypotheses for the documentation, (Tier 1) overlap between projects 1106, potential mode/mechanism(s) including disease mechanism and host factors of smoking related lung recommendation to 1107, 1109, 1116, 1117 endpoints and host factors of lung cancer cancer types in humans by October 2001. External Research Program (initiation and promotion) Davies, B N01142 Simplified aerosol delivery study Determine if simplified aerosol delivery devices (e.g., study results 03-Understanding Smoking and Health - On hold pending Sr. Mgmt CAG) can be utilized to answer specific basic research Exposure (Tier i) decision questions involved In smoking behavior and whether such devices could be developed into reduced harm products. Gullotta, F N01140 Fading Study Determine if nicotine/tar ratio of conventional products can study results 03-Understanding Smoking and Health - Start be modified to reduce constiluentexposure Exposure (Tier 1) Hirnikel, D Ng1137 Cigarette Burn Time Study Determine if smoke exposure in humans can be presentation, manuscript 03-Understanding Smoking and Health - Start quantified with a cigarette burn time study by May 1, Exposure (Tier 1) Smeke-Expesure-Versus£igareHe-Bnl 2002 mall"efil Stndy geef-rediewediedrna} Befe~Rtimeeatr8e-~ esFin~reinHum~stT5~ 2BBc Kinser,R NOt146 Scientificconsensus-LowTar/Compensation Summarizescientificconsensusonlowtar/compens ation presentation;report 03-UnderstandingSmokingandHealth• Start by February 28, 2001 Exposure (Tier 1) Davies, B N01141 Nicotine Kinetics as an Exposure Determinant Determine the contribution of nicotine kinetics to smoking study results 03-Understanding Smoking and Health - Start NiestiFleidaefiessiud7 behavior Exposure (Tieri) Tricker, A Ng1145 Biomarkers of exposure To identify and critically evaluate potential biomarkers of review documents; 03-Understanding Smoking and Health - Start exposure for the PI smoke chemistry list by December 1, recommendations for future Exposure (Tier 1) 2001. research Frledrichs, B N01182 Lung Inflammatlon Development of invlvo models: To evaluate rat lung documentation; SOP(s) 04-Understanding Smoking and Health - Test Start Inflammation after exposure to cigarette smoke and Systems/Experimental Models (Tier 1) selected smoke constituents Kindt, R No1188 Flow cytometric assays for investigating Understanding apoptosls/necrosis, single components: To SOPS 04-Understanding Smoking and Health - Test Start cytotoxicity/apoptosis establishflowcytometricassaysformechanisticendpoints Sysfems~ExperimentalM odels(Tier1) for understanding the mode of cytotoxic action of cigarette smoke and cigareHe smoke components in vivo oFAFTFOnflE'VIEtqPUqPOSES-llie/er p,7ZLO7YHOZ i Page2

WSAIINBIF02001 PLAN P. Leader P. Number Project Name Objective Deliverable Guidance Area Status per RPS / Comments Sanders, E N01102 Role of systematic biases in ETS epidemiology To assess the role of differential recall bias In both point report; suggestions for 06-Understanding Smoking and Health - Start estimates and dose-response relationships in ETSAung possible research project Epidemiology (Tier 2) cancer epidemiology In order to avoid such biases in future studies by the fourth quarter of 2001. Schorp, M N01104 Haemoglobln adducts of aromatic amines (AA) To critically evaluate the validity of literature reports on review documents, 06-Understanding Smoking and Health - Start aromatlcaminehaemoglobinadductsasameansof recommendatlonsforfuture Epidemiology (Tier 2) assessing exposure in smokers and nonsmokers reporting research exposure to ETS by end of July 2001. Schorp, M N01103 8-HDG Adducts Complete a literature study on 8-hydroxry-2'• final report OB-Understanding Smoking and Health - Start deoxyguanosine (8-HDG) adducts for the purpose of Epidemiology (Tier 2) forming a firm scientific position of the existence of such adducts as a consequence of ETS exposure. Tricker, A N01105 Active smoking, ETS exposure and risk of breast To critically evaluate epidemiological studies on the publication(s) of summary 06-Understanding Smoking and Health - Start cancer association between both active smoking and exposure to evaluation Epidemiology (Tier 2) ETS and risk of breast cancer, and the hypothesized mechanisms by December 1, 2001. Lau, R N01133 ETS exposure and biomarkers of effect In the To obtain data of non-smoker's exposure to ETS in data report 07-Understanding Smoking and Health - Hazard Start Total Exposure Study (TES) the pilot Total Exposure Study, and to evaluate the (Tier2) potential information to be yielded In theTES by June subjeeignsup of I ~ 2001. edby#he ~S-v'nri.,an:zrsv~.t,roR-HHetren-smakinggraupef- the p let TES by jamea y 20027 Davies, B N01166 Monoamine oxidase inhibitors (MAO-I) as Determine to whatextent MAOPs play an role in study results 08-Understanding Smoking and Health- Start determinants of exposure smoking behavior and if that Information can be used Exposure (Tier 2) to help develop reduced harm products Biedis ' stedy Beterrnlneihebiedlspe .. eets-. Himikel, D N01158 Validation of CFD Model Flovent To submita publication to a peer-reviewed journal on manuscript 08-Understanding Smoking and Health - Start the validation of the Flovent Exposure (Tier 2) TosubmiFa+nenuseripHheEwekda[esihe~y- e__~Rati__ _-___ --___._. __ ,h_ .,,,. E ..-_,:,_.:__ testreem-teihe-predkVed-mede Hirnikel, D N01155 ETS Testing Protocol Development To develop a recommendation to the SRRC on testing presentations, manuscript 08-Understanding Smoking and Health - Start protocols for ETS reduction technology (real time Exposure (Tier 2) Devele sensors by Dr. Jenkins and VOC removal by Dr. fer-a-Perf..rn,ar,ee Eveluatien-aFemAir-Gleaning- Shaughnessy) by December 10, 2001. ,.av ce to RedueeE~;ri,ed "s.;n.ns.tesnd- 6aseedsEenieminants PresemetL,rrorscle it fie data of a t;st,;,etheo and example-eppkieatierreneseleet4eeMrelagq-tesewe-as-a- petential made! for peKo aneaeveleatiene-efaif-ele ' i 09Zb09480Z I eFAFTFORREVIEWPURPOSES~i&9/m - -- Page4